Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova demonstrated notable financial improvement, with a year-over-year operating margin increase of 180 basis points, driven by gross margin expansion and effective management of selling, general, and administrative expenses. The company reported mid-single-digit revenue growth of 6.7% for 2024, supported by the anticipated launch of the Essenz heart-lung machine and expected organic growth of 7.0-8.0% in the Cardiopulmonary segment for 2025. Additionally, LivaNova's production capacity for oxygenators improved by 10% in 2024, with expectations for a further 10-15% increase in 2025, positioning the firm favorably as it prepares to capitalize on the recovery of elective procedures post-pandemic.

Bears say

LivaNova's recent financial performance shows signs of slowing growth, with neuromodulation sales increasing by only 1.0% to $137.6 million, significantly down from 8.8% growth in the previous quarter. The company's bear case scenario outlines potential revenue growth stagnating in the low single digits due to ongoing challenges in both the Neuromodulation and Cardiovascular segments, compounded by operating margin contraction and earnings that may fall below consensus estimates. Furthermore, while LivaNova's 2025 revenue guidance is slightly below expectations, its organic revenue growth has already shown a decline, dropping to 7% in the fourth quarter from 12% in the third quarter.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.